These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 8083704

  • 1. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial.
    Souhami RL, Rudd R, Ruiz de Elvira MC, James L, Gower N, Harper PG, Tobias JS, Partridge MR, Davison AG, Trask C.
    J Clin Oncol; 1994 Sep; 12(9):1806-13. PubMed ID: 8083704
    [Abstract] [Full Text] [Related]

  • 2. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.
    Furuse K, Fukuoka M, Nishiwaki Y, Kurita Y, Watanabe K, Noda K, Ariyoshi Y, Tamura T, Saijo N.
    J Clin Oncol; 1998 Jun; 16(6):2126-32. PubMed ID: 9626212
    [Abstract] [Full Text] [Related]

  • 3. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study.
    Goodman GE, Crowley JJ, Blasko JC, Livingston RB, Beck TM, Demattia MD, Bukowski RM.
    J Clin Oncol; 1990 Jan; 8(1):39-47. PubMed ID: 2153194
    [Abstract] [Full Text] [Related]

  • 4. Cisplatin/etoposide versus ifosfamide/etoposide combination chemotherapy in small-cell lung cancer: a multicenter German randomized trial.
    Wolf M, Havemann K, Holle R, Gropp C, Drings P, Hans K, Schroeder M, Heim M, Dommes M, Mende S.
    J Clin Oncol; 1987 Dec; 5(12):1880-9. PubMed ID: 2824710
    [Abstract] [Full Text] [Related]

  • 5. Experience of a German multicenter study group with ifosfamide in small cell lung cancer.
    Havemann K, Wolf M, Drings P, Hans K, Schroeder M, Holle R, Flechtner H, Goerg R, Becker H.
    Semin Oncol; 1989 Feb; 16(1 Suppl 3):9-18. PubMed ID: 2539648
    [Abstract] [Full Text] [Related]

  • 6. Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer.
    Ohnoshi T, Hiraki S, Ueoka H, Kiura K, Kamei H, Horiguchi T, Kodani T, Maeda T, Tabata M, Shibayama T.
    Cancer; 1993 Sep 01; 72(5):1597-601. PubMed ID: 8394202
    [Abstract] [Full Text] [Related]

  • 7. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D.
    J Clin Oncol; 1999 Aug 01; 17(8):2300-8. PubMed ID: 10561291
    [Abstract] [Full Text] [Related]

  • 8. Early versus late alternating chemotherapy in small-cell lung cancer. Swiss Group for Clinical Cancer Research (SAKK).
    Joss RA, Bacchi M, Hürny C, Bernhard J, Cerny T, Martinelli G, Leyvraz S, Senn HJ, Stahel R, Siegenthaler P.
    Ann Oncol; 1995 Feb 01; 6(2):157-66. PubMed ID: 7786823
    [Abstract] [Full Text] [Related]

  • 9. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
    Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S, Norwegian Lung Cancer Study Group.
    J Clin Oncol; 2002 Dec 15; 20(24):4665-72. PubMed ID: 12488411
    [Abstract] [Full Text] [Related]

  • 10. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine.
    Johnson BE, Bridges JD, Sobczeck M, Gray J, Linnoila RI, Gazdar AF, Hankins L, Steinberg SM, Edison M, Frame JN, Pass H, Nesbitt J, Holden D, Mulshine JL, Glatstein E, Ihde DC.
    J Clin Oncol; 1996 Mar 15; 14(3):806-13. PubMed ID: 8622028
    [Abstract] [Full Text] [Related]

  • 11. Cyclic-alternating versus response-oriented chemotherapy in small-cell lung cancer: a German multicenter randomized trial of 321 patients.
    Wolf M, Pritsch M, Drings P, Hans K, Schroeder M, Flechtner H, Heim M, Hruska D, Mende S, Becker H.
    J Clin Oncol; 1991 Apr 15; 9(4):614-24. PubMed ID: 1648598
    [Abstract] [Full Text] [Related]

  • 12. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D, Mari D, Graziano F, Isidori P, Cetto G, Pasini F, Santo A, Cellerino R.
    Cancer; 1997 Dec 15; 80(12):2222-9. PubMed ID: 9404698
    [Abstract] [Full Text] [Related]

  • 13. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M, Ochi Y, Kadota A, Akusawa H, Kisohara A, Takahashi N, Koya Y, Horie T.
    Oncol Rep; 2000 Dec 15; 7(2):305-10. PubMed ID: 10671676
    [Abstract] [Full Text] [Related]

  • 14. Alternating chemotherapy with cyclophosphamide, doxorubicin, vincristine and cisplatin, etoposide followed by prophylactic cranial and thoracic irradiation for small cell lung cancer (SCLC): long-term results.
    Ardizzoni A, Fusco V, Pennucci C, Baldini E, Orsatti M, Vitale V, Bonavia M, Baracco F, Mereu C, Rosso R.
    Anticancer Res; 1991 Dec 15; 11(2):681-4. PubMed ID: 1648333
    [Abstract] [Full Text] [Related]

  • 15. Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group.
    Johnson DH, Bass D, Einhorn LH, Crawford J, Perez CA, Bartolucci A, Omura GA, Greco FA.
    J Clin Oncol; 1993 Jul 15; 11(7):1223-9. PubMed ID: 8391064
    [Abstract] [Full Text] [Related]

  • 16. Concurrent cisplatin, prolonged oral etoposide, and vincristine plus chest and brain irradiation for limited small cell lung cancer: a phase II study of the Southwest Oncology Group (SWOG-9229).
    Thomas CR, Giroux DJ, Stelzer KJ, Craig JB, Laufman LR, Taylor SA, Goodwin JW, Crowley JJ, Livingston RB.
    Int J Radiat Oncol Biol Phys; 1998 Mar 15; 40(5):1039-47. PubMed ID: 9539558
    [Abstract] [Full Text] [Related]

  • 17. Interdigitating versus concurrent chemotherapy and radiotherapy for limited small cell lung cancer.
    Komaki R, Shin DM, Glisson BS, Fossella FV, Murphy WK, Garden AS, Oswald MJ, Hong WK, Roth JA, Peters LJ.
    Int J Radiat Oncol Biol Phys; 1995 Feb 15; 31(4):807-11. PubMed ID: 7860392
    [Abstract] [Full Text] [Related]

  • 18. [Alternating chemotherapeutic treatment in patients with localized undifferentiated small-cell carcinoma of the lung].
    Navarro M, Mur E, Jolis L, Bellmunt J, Bodi R, Solé LA, Rubio D.
    Rev Clin Esp; 1991 Oct 15; 189(5):209-12. PubMed ID: 1666192
    [Abstract] [Full Text] [Related]

  • 19. Influence of age on the treatment of limited-stage small-cell lung cancer.
    Siu LL, Shepherd FA, Murray N, Feld R, Pater J, Zee B.
    J Clin Oncol; 1996 Mar 15; 14(3):821-8. PubMed ID: 8622030
    [Abstract] [Full Text] [Related]

  • 20. Prolonged, alternating chemotherapy for extensive small cell lung cancer. A Southwest oncology Group study.
    Livingston RB, Crowley JJ, Thompson T, Williamson SK, Meyers FJ, O'Rourke T, Neefe JR.
    Cancer; 1993 Jun 01; 71(11):3509-13. PubMed ID: 8387881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.